Michael Murray, MD
Family Medicine · Reedsville, PANPI 1154344877
Payments from drug & device makers
Across 205 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$532
- Pfizer$522
- Novo Nordisk$324
- AbbVie$199
- Novartis$147
- AstraZeneca$128
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,059100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $532 |
| Pfizer | 48 | $522 |
| Novo Nordisk | 20 | $324 |
| AbbVie(2 entities) | 9 | $199 |
| Novartis | 10 | $147 |
| AstraZeneca | 9 | $128 |
| Phathom Pharmaceuticals, Inc. | 1 | $122 |
| Amgen | 7 | $109 |
| Abbott | 6 | $107 |
| Sanofi | 1 | $98 |
| E.r. Squibb & Sons, L.L.C. | 6 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Lilly USA, LLC | 5 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Exact Sciences | 2 | $51 |
| Boehringer Ingelheim | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| CSL Behring | 2 | $28 |
| Biogen | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Merck | 1 | $15 |
| Bayer | 1 | $13 |
| Philips North America LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$122
How this compares
$3,059 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $223,956 |
| OzempicSemaglutide | 140 | $157,428 |
| TrulicityDulaglutide | 63 | $75,727 |
| JardianceEmpagliflozin | 71 | $72,827 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $54,987 |
| JanuviaSitagliptin Phosphate | 27 | $29,542 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $24,015 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $20,742 |
| Advair HfaFluticasone Propion/Salmeterol | 48 | $18,837 |
| Risperidone ErRisperidone Microspheres | 13 | $18,812 |
| XareltoRivaroxaban | 14 | $15,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $14,628 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $14,431 |
| LinzessLinaclotide | 23 | $14,364 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $13,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $522 | $229,474238 claims |
| Novo NordiskOzempic | $324 | $157,428140 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $532 | $117,893213 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $40 | $86,04399 claims |
| Lilly USA, LLCTrulicity | $75 | $75,72763 claims |
| MerckJanuvia | $15 | $29,54227 claims |
| Johnson & JohnsonXarelto | $29 | $15,49014 claims |
| AbbVieLinzess | $199 | $14,36423 claims |
| NovartisEntresto | $147 | $10,78612 claims |
| AstraZenecaBreztri Aerosphere | $128 | $8,70614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Reedsville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.